Anticipated $0.34 EPS for Supernus Pharmaceuticals, Inc. (SUPN) as of May, 8

April 17, 2018 - By Darrel Chase

Big Money Sentiment increased to 1.1 in 2017 Q4. It has change of 0.12, from 2017Q3’s 0.98. The ratio improved due to Supernus Pharmaceuticals, Inc. positioning: 22 sold and 93 reduced. 43 funds amassed holdings and 83 increased holdings. Investors holded 48.75 million in 2017Q3 but now own 47.19 million shares or 3.19% less.
Axa invested in 0.03% or 189,048 shs. Mason Street Advisors Ltd Liability Com holds 13,333 shs or 0.01% of its capital. Ubs Asset Mgmt Americas stated it has 241,076 shs or 0.01% of all its holdings. Bnp Paribas Arbitrage has 20,664 shs. Argent Cap Mngmt Limited Com reported 0.09% stake. Pub Sector Pension Invest Board has 48,516 shs. Moreover, Amalgamated Bancorp has 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Raymond James reported 7,192 shs. First Limited Partnership holds 0% or 42,559 shs in its capital. Clarivest Asset Limited Company stated it has 18,302 shs or 0.01% of all its holdings. Oppenheimer Asset Management Incorporated invested in 14,959 shs. Susquehanna Intl Gru Llp invested 0% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Louisiana State Employees Retirement Sys holds 0.04% or 22,100 shs. Metropolitan Life Ny invested in 15,717 shs. Impact Advsrs Ltd Liability Company holds 0.5% or 29,180 shs in its capital.

Supernus Pharmaceuticals, Inc. registered $10.98 million net activity with 0 buys and 8 sales since January 2, 2018. On Wednesday, January 17 Vaughn Victor sold $1.12M worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). On Thursday, January 11 $2.18 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was sold by PATRICK GREGORY S.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s quarterly earnings will be reported On May, 8., according to RTT. Analysts expect change of 78.95 % or $0.15 from previous year’s $0.19 EPS compared to current’s $0.34 EPS. If $0.34 is reported, SUPN’s profit will reach $17.53M for 33.31 P/E. Wall Street forecasts -22.73 % negative EPS growth as of May, 8. Its shares touched $45.3 on during the last trading session after 0.11% change.Currently Supernus Pharmaceuticals, Inc. is uptrending after 46.59% change in last April 17, 2017. SUPN has 507,660 shares volume. The stock outperformed the S&P 500 by 35.04%.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

Total analysts of 8 have positions in Supernus Pharmaceuticals (NASDAQ:SUPN) as follows: 7 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 88%. Since October 18, 2017 according to StockzIntelligence Inc Supernus Pharmaceuticals has 14 analyst reports. On Friday, October 20 Stifel Nicolaus maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating. Stifel Nicolaus has “Hold” rating and $47.0 target. On Friday, October 27 the rating was maintained by Piper Jaffray with “Hold”. In Tuesday, January 2 report Stifel Nicolaus maintained the stock with “Buy” rating. On Wednesday, November 8 the stock has “Buy” rating by Stifel Nicolaus. The stock rating was initiated by FBR Capital with “Buy” on Wednesday, October 18. The stock rating was maintained by B. Riley & Co with “Buy” on Wednesday, November 8. On Monday, October 23 the company was maintained by Cowen & Co. On Monday, November 6 the stock has “Buy” rating by Cantor Fitzgerald. On Wednesday, February 28 Cantor Fitzgerald maintained the shares of SUPN in report with “Buy” rating. The stock rating was maintained by Piper Jaffray with “Hold” on Wednesday, February 28.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.The company has $2.34 billion market cap. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.The P/E ratio is 42.14. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.